| Investor | Commodore Capital Lp |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Commodore Capital Lp . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | 13G | EYPT / EyePoint, Inc. | 4,250,000 | |||||
| 2026-06-02 | 13G | EDIT / Editas Medicine, Inc. | 16,045,802 | |||||
| 2026-05-28 | 13G | 500,000 | ||||||
| 2026-05-15 | 13G/A | ELVN / Enliven Therapeutics, Inc. | 6,022,957 | 4,800,940 | ||||
| 2026-05-15 | 13G/A | TYRA / Tyra Biosciences, Inc. | 3,375,000 | 2,475,000 | ||||
| 2026-05-15 | 13G/A | PEPG / PepGen Inc. | 3,544,101 | 4,475,000 | ||||
| 2026-05-15 | 13G/A | PALI / Palisade Bio, Inc. | 9,690,665 | 12,366,776 | ||||
| 2026-05-15 | 13G/A | IKT / Inhibikase Therapeutics, Inc. | 6,807,507 | 14,054,940 | ||||
| 2026-05-15 | 13G/A | LBRX / LB Pharmaceuticals Inc | 1,225,000 | 1,972,369 | ||||
| 2026-05-15 | 13G/A | ANRO / Alto Neuroscience, Inc. | 3,245,628 | 3,588,180 | ||||
| 2026-05-04 | 13G | RLMD / Relmada Therapeutics, Inc. | 5,505,527 | |||||
| 2026-04-24 | 13G | JATT / JATT II Acquisition Corp. | 500,000 | |||||
| 2026-04-02 | 13G | KPTI / Karyopharm Therapeutics Inc. | 1,935,609 | 1,950,000 | ||||
| 2026-03-16 | 13G | ANTX / AN2 Therapeutics, Inc. | 3,697,435 | |||||
| 2026-03-11 | 13G | PEPG / PepGen Inc. | 3,544,101 | |||||
| 2026-02-24 | 13G | IMUX / Immunic, Inc. | 0 | 13,350,121 | ||||
| 2026-02-17 | 13G/A | COGT / Cogent Biosciences, Inc. | 10,208,060 | 2,802,905 | ||||
| 2026-02-17 | 13G/A | PCSC / Perceptive Capital Solutions Corp | 750,000 | 0 | ||||
| 2026-02-17 | 13G/A | TERN / Terns Pharmaceuticals, Inc. | 5,700,000 | 1,475,000 | ||||
| 2026-02-17 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 2,367,884 | 4,383,508 | ||||
| 2026-02-17 | 13G/A | DRUG / Bright Minds Biosciences Inc. | 500,000 | 18,851 | ||||
| 2026-02-17 | 13G/A | DFTX / Definium Therapeutics, Inc. | 7,428,775 | |||||
| 2026-02-17 | 13G/A | ANRO / Alto Neuroscience, Inc. | 3,190,267 | 3,245,628 | ||||
| 2026-02-09 | 13G | CATX / Perspective Therapeutics, Inc. | 3,350,000 | 11,939,753 | ||||
| 2026-01-16 | 13G | IPSC / Century Therapeutics, Inc. | 13,043,478 | |||||
| 2025-11-17 | 13G | AMLX / Amylyx Pharmaceuticals, Inc. | 5,650,000 | |||||
| 2025-11-14 | 13G/A | VRDN / Viridian Therapeutics, Inc. | 4,300,000 | 3,200,000 | ||||
| 2025-11-14 | 13G/A | CLDX / Celldex Therapeutics, Inc. | 3,350,000 | 3,028,335 | ||||
| 2025-11-14 | 13G/A | NRIX / Nurix Therapeutics, Inc. | 3,850,000 | 3,780,055 | ||||
| 2025-11-14 | 13G/A | COGT / Cogent Biosciences, Inc. | 6,408,060 | 10,208,060 | ||||
| 2025-11-14 | 13G/A | TERN / Terns Pharmaceuticals, Inc. | 4,650,000 | 5,700,000 | ||||
| 2025-11-14 | 13G/A | CDTX / Cidara Therapeutics, Inc. | 1,175,000 | 585,000 | ||||
| 2025-11-14 | 13G/A | TYRA / Tyra Biosciences, Inc. | 2,750,000 | 3,375,000 | ||||
| 2025-11-14 | 13G/A | RLAY / Relay Therapeutics, Inc. | 13,350,000 | 17,000,000 | ||||
| 2025-10-27 | 13G | ANRO / Alto Neuroscience, Inc. | 3,190,267 | |||||
| 2025-10-08 | 13G | PALI / Palisade Bio, Inc. | 9,690,665 | |||||
| 2025-10-03 | 13G | SABS / SAB Biotherapeutics, Inc. | 1,831,746 | 4,522,977 | ||||
| 2025-09-18 | 13G | LBRX / LB Pharmaceuticals Inc | 1,225,000 | |||||
| 2025-09-16 | 13G | TERN / Terns Pharmaceuticals, Inc. | 4,650,000 | |||||
| 2025-08-15 | 13G | ASMB / Assembly Biosciences, Inc. | 1,615,981 | |||||
| 2025-08-14 | 13G/A | NGNE / Neurogene Inc. | 800,000 | 427,866 | ||||
| 2025-08-14 | 13G/A | RLAY / Relay Therapeutics, Inc. | 10,000,000 | 13,350,000 | ||||
| 2025-08-14 | 13G | COGT / Cogent Biosciences, Inc. | 10,497,990 | 6,408,060 | ||||
| 2025-08-14 | 13G/A | SLDB / Solid Biosciences Inc. | 5,825,000 | 0 | ||||
| 2025-08-14 | 13G/A | CRDF / Cardiff Oncology, Inc. | 5,384,616 | 0 | ||||
| 2025-08-14 | 13G/A | ELVN / Enliven Therapeutics, Inc. | 4,100,000 | 6,022,957 | ||||
| 2025-08-14 | 13G/A | MRUS / Merus N.V. | 3,750,000 | 3,525,000 | ||||
| 2025-08-14 | 13G/A | COGT / Cogent Biosciences, Inc. | 10,497,990 | 5,269,224 | ||||
| 2025-07-02 | 13G | CDTX / Cidara Therapeutics, Inc. | 1,175,000 | |||||
| 2025-05-15 | 13G | RLAY / Relay Therapeutics, Inc. | 10,000,000 | |||||
| 2025-05-14 | 13G | TYRA / Tyra Biosciences, Inc. | 2,750,000 | |||||
| 2025-04-11 | 13G | VRDN / Viridian Therapeutics, Inc. | 1,924,074 | 4,300,000 | ||||
| 2025-04-10 | 13G | CLDX / Celldex Therapeutics, Inc. | 3,350,000 | |||||
| 2025-02-25 | 13G | SLDB / Solid Biosciences Inc. | 5,825,000 | |||||
| 2025-02-14 | 13G/A | NKTX / Nkarta, Inc. | 4,662,073 | 351,848 | ||||
| 2025-02-14 | 13G/A | CELC / Celcuity Inc. | 2,217,982 | 1,095,650 | ||||
| 2025-02-14 | 13G/A | CELC / Celcuity Inc. | 2,217,982 | 1,095,650 | ||||
| 2025-02-14 | 13G/A | DRUG / Bright Minds Biosciences Inc. | 400,000 | 500,000 | ||||
| 2025-02-14 | 13G | NRIX / Nurix Therapeutics, Inc. | 3,850,000 | |||||
| 2025-02-14 | 13G/A | NKTX / Nkarta, Inc. | 4,662,073 | 351,848 | ||||
| 2024-12-17 | 13G | CRDF / Cardiff Oncology, Inc. | 5,384,616 | |||||
| 2024-12-16 | 13G | MRUS / Merus N.V. | 3,350,000 | 3,750,000 | ||||
| 2024-12-11 | 13G | NGNE / Neurogene Inc. | 800,000 | |||||
| 2024-11-14 | 13G/A | VERA / Vera Therapeutics, Inc. | 5,450,000 | 2,475,000 | ||||
| 2024-11-14 | 13G/A | MRUS / Merus N.V. | 4,747,373 | 3,350,000 | ||||
| 2024-11-14 | 13G/A | ACET / Adicet Bio, Inc. | 4,250,000 | 0 | ||||
| 2024-11-14 | 13G/A | SYRE / Spyre Therapeutics, Inc. | 1,934,084 | 1,988,084 | ||||
| 2024-11-14 | 13G/A | COGT / Cogent Biosciences, Inc. | 6,172,086 | 10,497,990 | ||||
| 2024-11-14 | 13G/A | ADVM / Adverum Biotechnologies, Inc. | 10,000,000 | 0 | ||||
| 2024-11-14 | 13G/A | NKTX / Nkarta, Inc. | 2,730,000 | 4,662,073 | ||||
| 2024-11-14 | 13G/A | CATX / Perspective Therapeutics, Inc. | 3,350,000 | |||||
| 2024-11-14 | 13G/A | CELC / Celcuity Inc. | 2,492,886 | 2,217,982 | ||||
| 2024-11-14 | 13G/A | MNMD / Mind Medicine (MindMed) Inc. | 5,833,333 | 8,176,721 | ||||
| 2024-11-14 | 13G/A | VERA / Vera Therapeutics, Inc. | 5,450,000 | 3,900,000 | ||||
| 2024-11-14 | 13G/A | CCCC / C4 Therapeutics, Inc. | 3,800,000 | 3,410,384 | ||||
| 2024-11-14 | 13G/A | ELVN / Enliven Therapeutics, Inc. | 2,901,816 | 4,100,000 | ||||
| 2024-10-25 | 13G | DRUG / Bright Minds Biosciences Inc. | 400,000 | |||||
| 2024-10-17 | 13G | IKT / Inhibikase Therapeutics, Inc. | 6,807,507 | |||||
| 2024-06-21 | 13G | PCSC / Perceptive Capital Solutions Corp | 750,000 | |||||
| 2024-04-19 | 13G | ISR / Perspective Therapeutics Inc | 38,906,673 | |||||
| 2024-03-21 | 13G | MNMD / Mind Medicine (MindMed) Inc. | 5,833,333 | |||||
| 2024-02-14 | 13G/A | VERA / Vera Therapeutics, Inc. | 2,342,857 | 5,450,000 | ||||
| 2024-02-14 | 13G/A | CABA / Cabaletta Bio, Inc. | 1,458,367 | 1,900,000 | ||||
| 2024-02-14 | 13G/A | CBAY / CymaBay Therapeutics, Inc. | 5,738,500 | 0 | ||||
| 2024-02-14 | 13G/A | AMAM / Ambrx Biopharma Inc. | 0 | |||||
| 2024-02-14 | 13G/A | MRUS / Merus N.V. | 2,732,567 | 4,747,373 | ||||
| 2024-02-14 | 13G/A | CELC / Celcuity Inc. | 2,257,412 | 2,492,886 | ||||
| 2024-02-14 | 13G/A | SLNO / Soleno Therapeutics, Inc. | 885,741 | 700,000 | ||||
| 2024-02-14 | 13G/A | ADVM / Adverum Biotechnologies, Inc. | 6,158,141 | 10,000,000 | ||||
| 2024-02-14 | 13G/A | COGT / Cogent Biosciences, Inc. | 4,926,000 | 6,172,086 | ||||
| 2024-02-14 | 13G/A | IMUX / Immunic, Inc. | 2,873,563 | 0 | ||||
| 2024-02-14 | 13G/A | VERA / Vera Therapeutics, Inc. | 2,342,857 | 5,001,783 | ||||
| 2024-02-14 | 13G/A | ELVN / Enliven Therapeutics, Inc. | 2,082,123 | 2,901,816 | ||||
| 2024-02-14 | 13G/A | VRDN / Viridian Therapeutics, Inc. | 2,020,166 | 1,924,074 | ||||
| 2024-02-14 | 13G/A | SABS / SAB Biotherapeutics, Inc. | 6,932,463 | 1,831,746 | ||||
| 2024-02-14 | 13G/A | SYRE / Spyre Therapeutics, Inc. | 1,834,084 | 1,934,084 | ||||
| 2024-01-19 | 13G | ACET / Adicet Bio, Inc. | 4,250,000 | |||||
| 2023-12-22 | 13G | CCCC / C4 Therapeutics, Inc. | 3,800,000 | |||||
| 2023-12-01 | 13G | SYRE / Spyre Therapeutics, Inc. | 1,834,084 | |||||
| 2023-11-03 | 13G | HARP / Harpoon Therapeutics, Inc. | 1,703,465 | |||||
| 2023-10-27 | 13G | NKTX / Nkarta, Inc. | 2,730,000 | |||||
| 2023-10-16 | 13G | SABS / SAB Biotherapeutics, Inc. | 6,932,463 | |||||
| 2023-10-12 | 13G | SLNO / Soleno Therapeutics, Inc. | 885,741 | |||||
| 2023-10-06 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 1,575,000 | 2,367,884 | ||||
| 2023-08-09 | 13G | VTGN / Vistagen Therapeutics, Inc. | 0 | 1,575,000 | ||||
| 2023-04-27 | 13G/A | AMAM / Ambrx Biopharma Inc. | 35,700,000 | 31,181,983 | ||||
| 2023-04-24 | 13G | ELVN / Enliven Therapeutics, Inc. | 1,448,640 | 2,082,123 | ||||
| 2023-04-20 | 13G | ADVM / Adverum Biotechnologies, Inc. | 6,158,141 | |||||
| 2023-03-30 | 13G | BLU / Bellus Health Inc | 5,303,557 | 6,579,359 | ||||
| 2023-03-03 | 13G/A | AMAM / Ambrx Biopharma Inc. | 35,700,000 | |||||
| 2023-03-03 | 13G | AMAM / Ambrx Biopharma Inc. | 26,250,000 | |||||
| 2023-02-28 | 13G/A | ELVN / Enliven Therapeutics, Inc. | 1,448,640 | |||||
| 2023-02-21 | 13G/A | IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF | 2,494,794 | 2,840,754 | ||||
| 2023-02-16 | 13G | VERA / Vera Therapeutics, Inc. | 2,342,857 | |||||
| 2023-02-14 | 13G/A | VRDN / Viridian Therapeutics, Inc. | 1,371,339 | 2,020,166 | ||||
| 2023-02-14 | 13G/A | IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF | 1,497,910 | 2,494,794 | ||||
| 2023-02-14 | 13G/A | CBAY / CymaBay Therapeutics, Inc. | 5,419,896 | 5,738,500 | ||||
| 2023-02-14 | 13G/A | CELC / Celcuity Inc. | 920,464 | 2,257,412 | ||||
| 2023-02-14 | 13G/A | BLU / Bellus Health Inc | 5,457,110 | 5,303,557 | ||||
| 2023-02-14 | 13G/A | KPTI / Karyopharm Therapeutics Inc. | 4,011,052 | 1,935,609 | ||||
| 2023-02-14 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 10,455,910 | 0 | ||||
| 2023-02-14 | 13G/A | COGT / Cogent Biosciences, Inc. | 2,281,315 | 4,926,000 | ||||
| 2023-02-14 | 13G/A | MRUS / Merus N.V. | 2,242,224 | 2,732,567 | ||||
| 2023-02-14 | 13G/A | IMUX / Immunic, Inc. | 3,766,576 | 2,873,563 | ||||
| 2023-01-13 | 13G | CABA / Cabaletta Bio, Inc. | 1,458,367 | |||||
| 2022-11-16 | 13G/A | STSA / Satsuma Pharmaceuticals Inc | 3,711,286 | 0 | ||||
| 2022-10-24 | 13G | IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF | 1,497,910 | |||||
| 2022-10-21 | 13G | IMUX / Immunic, Inc. | 3,766,576 | |||||
| 2022-05-19 | 13G | VRDN / Viridian Therapeutics, Inc. | 1,371,339 | |||||
| 2022-05-16 | 13G | MRUS / Merus N.V. | 2,242,224 | |||||
| 2022-05-09 | 13G | KPTI / Karyopharm Therapeutics Inc. | 4,011,052 | |||||
| 2022-04-14 | 13G | VTGN / Vistagen Therapeutics, Inc. | 10,455,910 | |||||
| 2022-02-14 | 13G/A | STSA / Satsuma Pharmaceuticals Inc | 3,208,761 | 3,711,286 | ||||
| 2022-02-14 | 13G/A | GNCA / Genocea Biosciences Inc | 2,871,624 | 3,079,756 | ||||
| 2022-02-14 | 13G/A | COGT / Cogent Biosciences, Inc. | 2,141,339 | 2,281,315 | ||||
| 2022-02-14 | 13G/A | CBAY / CymaBay Therapeutics, Inc. | 3,529,465 | 5,419,896 | ||||
| 2022-02-14 | 13G/A | CELC / Celcuity Inc. | 830,967 | 920,464 | ||||
| 2022-02-14 | 13G | BLU / Bellus Health Inc | 5,457,110 | |||||
| 2021-11-04 | 13G | COGT / Cogent Biosciences, Inc. | 2,141,339 | 2,141,339 | ||||
| 2021-10-19 | 13G/A | STSA / Satsuma Pharmaceuticals Inc | 2,119,245 | 3,208,761 | ||||
| 2021-07-12 | 13G | CBAY / CymaBay Therapeutics, Inc. | 3,529,465 | |||||
| 2021-07-09 | 13G | CELC / Celcuity Inc. | 830,967 | |||||
| 2021-03-31 | 13G | GNCA / Genocea Biosciences Inc | 2,871,624 | |||||
| 2021-03-15 | 13G | 859319303 / Sterling Financial Corp | 2,119,245 |
